NXgenPort today announced that it has entered into a license agreement with Mayo Clinic to develop and test an implantable chemo-port catheter.
NXgenPort’s technology has chemo-port efficacy with sensor technology to measure and remotely monitor the early onset of complications by reporting and tracking patient response during treatment.
Get the full story on our sister site, Medical Tubing + Extrusion.